Atomwise uses Deep Learning Neural Networks to help discover new medicines. Atomwise achieves the world’s best results for new drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise predicts drug candidates for pharmaceutical companies, startups, and research institutions. The Company's tools can tell the difference between great drug candidates and toxic ones, and discover new uses for old medicines.

Company Growth (employees)
San Francisco, US
Size (employees)
11 (est)+10%
Atomwise was founded in 2012 and is headquartered in San Francisco, US

Atomwise Office Locations

Atomwise has an office in San Francisco

Atomwise Data and Metrics

Summary Metrics

Founding Date


Total Funding

$6.6 m

Latest funding size

$6 m

Time since last funding

about 2 years


Atomwise's latest funding round in June 2015 was reported to be $6 m. In total, Atomwise has raised $6.6 m

Traffic Overview of Atomwise

Atomwise Online and Social Media Presence

Atomwise News and Updates

Atomwise launches research program to accelerate drug discovery with AI

Atomwise, which uses artificial intelligence (AI) to accelerate drug discovery for diseases like Ebola, multiple sclerosis, and leukemia, today announced the launch of its Artificial Intelligence Molecular Screen (AIMS) program. The program is free and open to any university-affiliated scientist in …

Atomwise Company Life and Culture

You may also be interested in